Abstract Library

#2887 CHOI Criteria Are More Accurate Than RECIST in Advanced Pancreatic Neuroendocrine Tumors Treated with Sunitinib: Data from the CRIPNET-GETNE1504 Study

Introduction: Comparative data suggest greater accuracy of Choi vs RECIST in some cancers such as pancreatic neuroendocrine tumors (panNET) treated with antiangiogenic agents.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Jimenez-Fonseca P, Fernandez del Valle A, Solis M, Garcia Carbonero R, Custodio A,

Keywords: CHOI, RECIST, Response, Sunitinib, Survival,

#2217 Prognostic Impact of CHOI Response Criteria Compared to RECIST in Grade 1-2 Advanced Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study-NCT02841865)

Introduction: Response Evaluation Criteria In Solid Tumors (RECIST) are not presumably the most optimal option for predicting the benefit of antiangiogenic drugs in neuroendocrine tumors (NETs), given that tumor shrinkage is not frequent, and qualitative changes in tumor tissues are to be expected.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Carmona-Bayonas A, Fernandez del Valle A, Solis M, Matos I, Garcia-Carbonero R,

Keywords: CHOI criteria, pancreatic neuroendocrine tumor, RECIST, response, survival,

#1932 Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study

Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Solis-Hernandez M, Carmona-Bayonas A, Calvo-Temprano D, Nuñez B, Custodio A,

Keywords: sunitinib, PNET, choi, recist,

#1760 The Efficacy and Safety of Sunitinib in Patients with Advanced Well Differentiated Pancreatic Neuroendocrine Tumors: Focus on Response Rate

Introduction: In a pivotal phase 3 study (NCT00428597) SU demonstrated a significant increase in progression-free survival (PFS) vs placebo following early study termination.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Raymond E, Kulke M, Qin S, Yu X, Schenker M,

Keywords: pNET, survival, sunitinib,

#1334 Early Evaluation of Sunitinib in Treatment of Advanced Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) by CT Imaging: RECIST or Choi Criteria?

Introduction: There is no study to assess RECIST and Choi criteria in evaluating response of advanced GEP-NENs treated with sunitinb.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Luo Y, Chen J, Li Z, Feng S,

Keywords: gastroenteropancreatic neuroendocrine neoplasm, sunitinib, time to progression, computed tomography,